139 results about "Ribosome" patented technology

The invention relates to a brand-new microbial natural metabolite, namely Fcl-8, which is derived from a fermentation solution of Xenorhabdius budapestensis XBD8, and is characterized in that the Fcl-8 is a new microbial natural metabolite, namely Fcl-8, which is derived from the fermentation solution of the Xenorhabdius budapestensis XBD8. The purified Fcl-8 is a snow white flocculent crystal and is very easy to dissolve in water, and the solid state of the purified Fcl-8 is as shown in Figure 1. The chemical structural formula of the Fcl-8 is as shown in a figure 2, the chemical formula is C57H102N14O12, the molecular weight is 1175.78744, and the typical secondary mass spectrum information of the Fcl-8 is as shown in a figure 3. The Fcl-8 is derived from a microbial natural metabolite, is novel in structure and high in biological activity, and has very high potential to be developed into a novel biopesticide.

The invention provides a macro virus group sequencing library construction method for removing host ribosome RNA through an enzyme method and a kit, and belongs to the technical field of biology. The method comprises the following steps: hybridizing total RNA (Ribonucleic Acid) of a sample with a DNA (Deoxyribose Nucleic Acid) probe aiming at host ribosome RNA to form a DNA / RNA hybrid chain; rNase H is used for digesting RNA in the hybrid chain, and DNase I is used for digesting the remaining DNA probe in the system; purifying to obtain virus RNA (Ribonucleic Acid); carrying out fragmentation treatment on the virus RNA; carrying out reverse transcription on the fragmented RNA to synthesize a first chain cDNA, then synthesizing a second chain cDNA, and carrying out terminal repair and dA tail addition to obtain double-chain cDNA; connecting the linker with the dT tail with the double-chain cDNA; and carrying out PCR amplification and purification on the connection product to obtain the macro virus group sequencing library. According to the construction method and the kit, the problem that the full-length sequence of the virus cannot be obtained from a low-load sample can be solved.

The invention provides a compound as shown in a formula (I), and a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition thereof, which have better antibacterial and anti-inflammatory effects, can be used as an antibiotic, and can be used for preparing a pharmaceutical preparation for preventing and treating diseases. The compound can treat infection caused by pathogenic microorganisms resistant to erythromycin and telithromycin, and simultaneously acts on double targets of ribosome and topoisomerase.

Provided are a non-ribosomal antifungal peptide MaAFP1, a preparation method therefor and a use thereof. The molecular formula of the antifungal peptide MaAFP1 is C41H74N18O12, wherein an amino acid sequence from the N-terminus to the C-terminus is (D)Arg-(L)Arg(OH)-(D)Orn-(L)Thr-(D)Orn-(L)Arg(OH)-(D)Tyr. Fermentation is performed by using Metarhizium anisopliae CQMa421, a fermentation broth is collected, and separation and purification are performed by means of ion exchange chromatography and high performance liquid chromatography so as to obtain the antifungal peptide MaAFP1. The structure of MaAFP1 is analyzed by comprehensively using an Edman degradation method, mass spectrometry, infrared spectroscopy, nuclear magnetic resonance spectroscopy, and circular dichroism spectroscopy. By performing an in vitro bacteriostatic test, it is found that MaAFP1 has a good inhibitory effect on a variety of animal and plant pathogenic fungi, and has the value of the development of a novel antibacterial drug.

The application discloses a LAMP primer group, a kit and a detection method for detecting Pinus armandii rust fungus, and belongs to the technical field of genetic engineering. The application takes the specific nucleotide sequence of the large subunit ribosomal RNA of the Pinus armandii rust fungus as a target gene to design and screen a primer group which is specific and high in sensitivity, and can be used for LAMP detection of the Pinus armandii rust fungus. The LAMP primer group provided by the application has the advantages of high universality, high specificity, high sensitivity and good accuracy, and the detection limit can reach 4.5x10 ‑4 ng / μL, which is 100 times higher than the sensitivity of the LAMP detection of different species in the same genus in the prior art, the detection method can rapidly detect the Pinus armandii rust fungus from spore piles and host plant materials, and is suitable for the detection of Pinus armandii seedling materials in forest fields and customs quarantine ports.

Provided are a method for preparing scar-free circular RNA, and a recombinant nucleic acid molecule for preparing scar-free circular RNA and use thereof. The provided recombinant nucleic acid molecule based on the IRES stem-loop structure can be used for preparing a circular nucleic acid molecule completely free of exogenous sequences without altering any sequence of the IRES, thereby avoiding unpredictable effects on ribosome recruitment function caused by IRES mutations.

A cassette for the delivery of one or more mRNA is provided, the cassette comprising a 5' UTR, a Nodamura replicon, a ribosomal skipping polynucleotide, the one or more mRNA, a plant virus assembly origin polynucleotide ("OAS"), and a 3' UTR. In one aspect, the cassette further comprises a 5'mRNA cap. In a yet further aspect, the cassette does not comprise a poly A tail.

This invention relates to the field of bioinformatics, and particularly to a method and system for denoising single-cell immune repertoire sequencing data. The method includes data preprocessing and feature extraction, bidirectional collaborative denoising, intelligent comprehensive judgment and classification, data archiving and background learning, and result output. Compared to existing technologies that primarily rely on static thresholds for cell filtering, which struggle to comprehensively assess and eliminate multi-dimensional noise, leading to incomplete purification and the potential deletion of high-value cell information, this invention employs a systematic denoising scheme integrating multi-parameter dynamic threshold filtering, specific gene contamination analysis, and targeted optimization of VDJ data. It sets dynamic thresholds by integrating multi-dimensional quality control indicators such as UMI number, gene number, and the proportion of mitochondrial and ribosomal genes, and specifically identifies and filters interfering genes and background sequences. This enables refined and hierarchical removal of complex noise, significantly improving the overall quality of cell datasets and the accuracy of VDJ receptor sequence analysis.

This invention discloses a *Bacillus laterosporus* strain for the stable production of nonribosomal cyclic lipolipeptide and its construction method. The M1A gene in the Bogorol biosynthetic gene cluster is knocked out using CRISPR-Cas9 technology to block the Bogorol pathway, which competes with Brevicidine for substrates. Subsequently, the pMCCas9-S48 plasmid, which integrates S8 and S41 sgRNAs and their homologous arms as repair templates, is used to simultaneously knock out S8 and S41 family peptidase genes, preventing the expression of extracellular degradation enzymes. This invention also provides the application of the above strain in the preparation of nonribosomal cyclic lipolipeptide of Brevicidine and a method for preparing the nonribosomal cyclic lipolipeptide. This strain, through reducing metabolic competition and preventing product degradation, exhibits rapid cell growth, stable production of Brevicidine, and significantly reduced degradation rate, resulting in a 66.13% increase in fermentation yield compared to the unmodified strain. This invention solves the problems of degradation and unstable yield in the production of Brevicidine, provides an effective technical approach for the industrial production of Brevicidine, and provides important technical support for the development and application of novel antimicrobial peptide drugs.

An immunogenic composition comprising: a) one or more Plasmodium-derived ribosomal or ribosomal associated protein or immunogenic fragment thereof which has a sequence which is at least about 80%, 85%, 90%, 95%, 98%, 99% or 100% identical to a ribosomal or ribosomal associated protein or an immunogenic fragment of a ribosomal or ribosomal associated protein recited in FIG. 1; or a ribosomal or ribosomal associated protein or peptide or immunogenic fragment thereof as recited in FIG. 2 or FIG. 3; and / or b) a polynucleotide encoding one or more protein, peptide or immunogenic fragment of a); wherein the immunogenic composition is for use in eliciting an immune response in a subject to treat or prevent malaria. Also provided are Plasmodium-derived ETRAMPs and / or histones, or immunogenic fragments thereof, for use in eliciting an immune response in a subject, preferably to treat or prevent malaria.

The invention discloses an efficient ribosome imprinting sequencing library construction method, and belongs to the technical field of biology. In the enzyme digestion treatment step, a mixed enzyme system of RNase I and micrococcus nuclease is adopted to treat the cell lysis buffer, and the trinucleotide periodicity of RPFs can be remarkably improved to 80% or above. In the target fragment recovery step, the sucrose gradient ultracentrifugation step is omitted, the RPFs are directly recovered by gel electrophoresis, a plurality of enzyme reaction steps in library construction are optimized and integrated, and streptavidin magnetic beads are used for solid phase purification, so that the whole library construction period is greatly shortened from 7 days to 2.5 days. The method does not depend on special equipment such as ultracentrifugation, and can be completed in a conventional molecular biology laboratory. Besides, a multi-enzyme synergistic RNA terminal one-step modification system is innovatively constructed, single-tube one-step completion is realized, the terminal treatment efficiency and consistency are improved, and a key guarantee is provided for obtaining a high-quality and high-complexity Ribo-seq library.

Methods and kits of rapidly isolating molecules from a sample are provided. Methods of treating a subject in need thereof using the rapid isolation kits and / or methods described herein are also provided. In some embodiments, the molecules are selected from ribosomes, DNA, RNA, and protein. In some embodiments, the sample is selected from a tissue sample, a blood sample, a non-blood biological fluid sample, and a whole organism sample.

The present disclosure provides compositions, methods of making, and use of a circular ribonucleic acid (circRNA) therapeutic for targeted delivery to immune cells, including T cells, for effector functions such as B cell depletion, providing, among other things, methods of treating B cell-mediated diseases such as autoimmune disease and cancer, meeting the medical need for efficacious and safe therapies that overcome the disadvantages of ex vivo CAR T therapy. Provided by the present disclosure is a circRNA therapeutic comprising: (i) a circRNA comprising a ribosome recruiting element, and a coding sequence encoding a CAR comprising, for example, an anti-CD19 antibody or antigen-binding fragment thereof, and (ii) a targeting moiety (e.g., anti-CD5) that binds to an immune cell (e.g., a T cell), wherein the circRNA is in a delivery vehicle, and a targeting moiety that binds to a T cell is conjugated to the delivery vehicle (e.g., a lipid nanoparticle).

The use of different primer sets in reverse transcription incorporates tags allowing for the selective amplification of cDNA transcribed using the different primers. Primers targeting non-desired RNA sequences such as ribosomal RNA can be used to prevent subsequent amplification of cDNA transcribed from those non-coding fragments. Accordingly effective depletion of non-desired sequences after cDNA amplification can be achieved. Systems and methods of the invention have applications in whole-transcriptome analysis. Non-coding sequence targeting primers can include nucleotide analogs that, when enzymatically processed, prevent subsequent amplification. Library preparation can include single primer isothermal amplification (SPIA) techniques wherein an RNA sequence required for SPIA is included in random primers but is absent from primers targeting non-coding RNA.

The present disclosure relates to methods, devices and systems for exposing microorganisms or compositions comprising functional proteins to an oscillating electric field substantially free of a magnetic component in order to improve stress responses, survival and metabolite or protein production. In embodiments, a controller drives one or more insulated emitters with a true AC signal or pulsed DC signal, in stepped, swept or shuffled patterns of an electric field oscillating at one or more frequencies in the range 210 Hz to 99 kHz. Exposure to the field provides surmounting energy that enhances protein breathing, catalysis, and fundamental functions of multiprotein complexes including transcription factors and ribosomes, thereby improving stress resistance of microorganisms, their viability during fermentation, drying, storage, transport, and / or increasing production of functional or therapeutic proteins, metabolites or microbial lysates. The technology is applicable to manufacture of probiotics, therapeutics, metabolites, food, alcohol, feed and bioenergy, cosmetics, nutraceuticals and biopharmaceuticals..

The invention provides a preparation method for preparing a scar-free circular RNA (Ribonucleic Acid), a recombinant nucleic acid molecule for preparing the scar-free circular RNA and application of the recombinant nucleic acid molecule. The recombinant nucleic acid molecule based on the IRES stem-loop structure provided by the invention can be used for preparing a circular nucleic acid molecule in which an exogenous sequence is completely eliminated, and any sequence of IRES is not changed, so that the unpredictable influence of IRES mutation on recruitment of ribosome functions is avoided.

The invention discloses a genetically engineered bacterium for producing D-pantothenic acid based on a corynebacterium glutamicum CPSPC system as well as a construction method and application of the genetically engineered bacterium. Wild type C.glutamicum ATCC 13032 is taken as a chassis strain, and a functional combination of a glycine ribosome switch BsGR from bacillus subtilis and a promoter Ptuf / Ph36 is verified through fluorescent protein mCherry; a GCS system of escherichia coli and bacillus subtilis is introduced to the strain DPAg-15, genes related to synthesis of 5, 10-dimethyltetrahydrofolic acid are tested, it is found that serA delta197GTG / ATG significantly increases the yield of D-pantothenic acid, the yield of D-pantothenic acid of the constructed strain DPAj-2-tuf is increased to 23.06 g / L (63 h), the yield is 0.37 g / L / h, and the conversion rate is 0.17 g / g; the engineering strain DPAj-2-tuf is obtained by dynamically regulating and controlling a D-pantothenic acid synthesis path through a CPSPC system and combining plasmid overexpression serA delta197GTG / ATG, the yield of the engineering strain DPAj-2-tuf is increased by 2.1 times compared with that of a traditional method, and an efficient technical scheme is provided for producing D-pantothenic acid through a microbial fermentation method.

In the field of gene therapy, a major hurdle is the design and identification of constructs and gene therapy vectors providing therapeutic effects while displaying satisfactory safety profiles. In the treatment of Diamond-Blackfan Anemia (DBA), therapies alleviating several crucial anemia symptoms, such as blood or bone marrow cellularity, hemoglobin levels, erythrocytes levels, or platelet levels, while showing satisfactory safety profiles remain a challenge. The present invention provides constructs encoding ribosomal protein genes involved in DBA, such as genes encoding RPS19, RPS17, RPS24, RPS10, RPL35a, RPL11, RPS26, and RPL5, vectors, methods, cells, and medical uses thereof, addressing these challenges and finding particular applications in the field of autologous cell therapy treatment of DBA. Further, the present invention provides a non-genotoxic conditioning protocol for preparing a subject prior to cell therapy treatment for DBA using construct of the present invention.

The present invention relates to an oligonucleotide comprising: a) a nucleotide sequence of a broom-kojin-ricin loop (SRL) of a eukaryotic / mammalian 60S ribosomal subunit wherein the SRL nucleotide sequence comprises at least one adenine; and b) at least one cut-dependent marker; wherein the oligonucleotide is a single strand. Preferably, the oligonucleotides form at least one loop structure or stem-loop structure. In another aspect, the invention relates to a method of detecting active shiga toxin in a sample, the method comprising the steps of: a) providing at least one oligonucleotide according to the invention; b) providing a sample of shiga toxin to be detected; c) incubating the sample with at least one single-stranded oligonucleotide; and d) detecting a labeled signal, wherein the signal indicates the presence of Shiga toxin in the sample. The invention additionally comprises a kit comprising at least one oligonucleotide according to the invention.

This invention discloses a PhlD gene based on translation rate optimization and its applications, belonging to the fields of genetic engineering and protein engineering. Without altering the amino acid sequence of the PhlD protein, this invention optimizes the translation rate of the original PhlD sequence through synonymous codon substitution, enabling rapid translation within the coding domains. Translation deceleration sites are introduced into the contiguous regions of the coding sequence domains, matching the ribosomal translation rate with the protein co-translational folding process, significantly improving the soluble expression level of the PhlD protein. The PhlD gene with optimized translation rate results in a 5.5-fold increase in the soluble expression level of the encoded PhlD protein compared to the original sequence. Engineered bacteria containing this optimized gene show a 4-fold increase in the yield of phloroglucinol during fermentation compared to the control. This provides a core gene resource for the efficient soluble expression of the PhlD protein and the industrial production of phloroglucinol.

The present invention relates to the design of improved TALE protein fusions useful as sequence-specific genomic reagents, such as TALE-nucleases and TALE base editors, comprising series of nucleus localization signals (NLS), especially a fusion of at least two monopartite NLS, such as from C-myc (C-myc NLS) and / or from SV40 T antigen (SV40 T NLS), and at least one bi-partite NLS, such as from Nucleoplasmin (Nucleoplasmin NLS). The goal of these fusions is to produce safer TALE reagents to genetically modify genomes and / or its organisation in different types of cells for their potential use in gene therapy.

The invention discloses a lincRNA small peptide coding potential identification method and a lincRNA small peptide coding potential identification system, and belongs to the technical field of computer technology and bioinformatics. The method comprises the following steps: firstly, processing a lincRNA sequence into a standardized sequence set; identifying and integrating the deduplicated potential coding fragments to obtain a candidate coding region set; after extracting multi-dimensional feature codes of each region, performing fusion through a Mama model and a machine learning model to obtain a fusion prediction confidence coefficient and a label; and finally, judging the coding potential, if not, outputting a conclusion, if yes, deducing an amino acid sequence, calculating comprehensive sequencing confidence by combining multiple indexes, sequencing, and screening small peptide sets with high and low confidence according to a threshold value. According to the method, an efficient sequence state space modeling structure is introduced, dependence on ribosome sequencing or mass spectrum data is not needed, high-precision, low-complexity and extensible prediction of the potential small peptide coding capacity in the lincRNA sequence is achieved, and the technical defect that accuracy and calculation efficiency are difficult to consider at the same time in an existing method is overcome.

The application relates to the technical field of tumor drugs, in particular to application of METTL5 as a tumor immunotherapy targeting site. The base sequence of the METTL5 is shown in SEQ ID No. 1; wherein the METTL5 is a brand-new RNAm6A methyltransferase, is closely related to ribosome translation function, and can regulate the translation of a tumor immune key regulator IL-27; therefore, the METTL5 is used as the tumor immunotherapy targeting site, the expression of the METTL5 related genes or coding proteins is inhibited through targeting, the body anti-tumor immunity can be effectively stimulated, the METTL5 becomes the targeting site capable of enhancing the response rate of tumor immunotherapy, and the METTL5 used as the tumor treatment target point has a wide application prospect in the anti-tumor immunotherapy.

The invention provides a high-expression 5 'UTR-HHP1 sequence and application thereof, and belongs to the technical field of medicines. The DNA sequence is as shown in SEQ ID NO. 1. The sequence of the RNA is shown as SEQ ID NO. 2. According to the invention, 5 'UTR of a gene with extremely high expression efficiency and a natural 5' UTR sequence of a pathogen mRNA in human cells are found through an NCBI (National Center of Biotechnology Information) database. And through a BaidleHelix platform, carrying out ribosome load prediction and optimization design on the candidate UTR and carrying out secondary structure prediction, and selecting the UTR with a relatively good prediction effect for verification. And a DNA-RNA two-dimensional verification system is established.

This disclosure generally relates to fusion proteins comprising TAL Arrays targeting a repetitive element and a transposase domain comprising amino terminal deletions, as well as dual cysteine rich domains (CRD), for targeting site-specific transposition into ribosomal DNA (rDNA) repeats or LINE1 repetitive elements, polynucleotides and vectors encoding the fusion proteins, and methods of use therefor.

A rRNA-mRNA chimera comprising a mRNA molecule, a small rRNA molecule, and a linker covalently linking the rRNA molecule and the mRNA molecule. Nucleic acid constructs, ribosomes, hosts cells, and kits comprising the rRNA-mRNA chimera, and method of producing a proteinaceous product by covalently linking via a linker a rRNA molecule to a mRNA encoding the proteinaceous product.

The application discloses a kind of lncRNA subcellular localization prediction method based on lightGBM, comprising, first, the nucleotide of the front section multiple of known lncRNA sequence is intercepted as sequence sample one;Then by based on single strand multiclass position-specific three nucleotide bias and reverse complementary kmer, sequence sample one is respectively characterized coding, the combination of two kinds of feature coding is vector;Use lightGMB as learning algorithm;Using 5-fold cross validation optimization reverse complementary kmer and LightGBM's hyperparameter;Most intercept unknown lncRNA sequence front end multiple bases as sequence sample two, and its single strand multiclass position-specific three nucleotide bias and the combination of optimized reverse complementary kmer feature coding is input in trained lightGBM, will obtain its localization subcellular type, the patent of the application can be according to long-chain non-coding RNA sequence prediction in cytoplasm, nucleus, ribosome, cytosol, exosome five subcellular positions, the application realizes simply, and prediction precision is high.

The invention belongs to the technical field of lipopeptide preparation, genetic engineering and biological medicine, and particularly relates to novel double-fat-chain lipopeptide as well as a preparation method and application thereof. According to the invention, a novel artificial gene cluster rhc is successfully constructed through precise editing and recombination of a functional module of a natural non-ribosomal lipopeptide gene cluster, and after heterologous expression of the gene cluster, a brand new double-fat-chain lipopeptide product Rhcolide A can be synthesized; the rhc gene cluster used for preparing the novel double-fat-chain lipopeptide Rhcolide A is the first artificial double-fat-chain lipopeptide synthetic gene cluster constructed through genetic engineering modification. A biological function test verifies and finds that Rhcolide A has excellent ferroptosis sensitizing activity, can be used as a ferroptosis sensitizer to be combined with a ferroptosis inducer to prepare a non-small cell carcinoma resisting drug, provides a brand new drug molecular entity for treatment of non-small cell carcinoma, and has important clinical application value and industrialization prospect.

This invention application discloses a gene regulating maize kernel development. ZmRH51 This application focuses on the encoded proteins, functional markers, and applications of maize kernel mutants. m223 Using this as the basic material, its heterozygotes were crossed with Zheng 58 (Z58) to construct the F2 segregating population. Phenotypic identification and cytological observation were performed on the progeny segregating population. Controlling populations were obtained through genetic analysis, BSR-seq analysis, and map-based cloning. m223 Genes with mutant phenotypes ZmRH51 This gene is located in the nucleolar region and encodes an RNA helicase belonging to the DEAD-Box gene family. Studies have shown that... ZmRH51 It participates in ribosome assembly and can influence the processing of pre-rRNA in maize kernels; and further mining yields... ZmRH51 The superior allelic variant genotype of this gene in terms of grain thickness can be utilized to improve grain thickness and 100-grain weight, thereby increasing yield. Furthermore, the distribution and utilization potential of different haplotypes in inbred lines were studied, providing technical support and excellent germplasm resources for the utilization of this gene.

The invention discloses a double PCR (Polymerase Chain Reaction) detection kit for trichina and toxoplasma gondii and application of the double PCR detection kit. The kit comprises upstream and downstream primer pairs for detecting trichina and toxoplasma gondii respectively, 2 * Taq Master Mix and non-enzyme water, the primer pair for detecting the trichina specifically aims at a complete sequence of a trichina T1 isolate ISS 003 ribosome small subunit gene, and the primer pair for detecting the toxoplasma gondii specifically aims at a toxoplasma gondii H66R isolate 529REP repetitive sequence region. The duplex PCR detection system disclosed by the invention is good in specificity, and does not generate cross reaction with other common polypide bodies; corresponding target fragments can be amplified when trichina and toxoplasma gondii are detected, and no amplified fragment appears when common pig parasites are detected, so that the specificity is high; the detection limit is 0.10 ng / mu L, so that the kit has relatively high sensitivity. In conclusion, the detection kit disclosed by the invention is high in sensitivity, strong in specificity, mild in reaction condition, short in reaction period and high in detection flux, and can be used for rapidly screening the toxoplasma gondii and trichina in meat products and live pigs in various scenes.